Ferrous Gluconate

Introduction Overview

Generic Name

ferrous gluconate

Brand Name

Fergon, Ferate, Ferralet, Simron

Dosage Form

oral tablet (240 mg; 324 mg)

Drug Class

Iron products

Pharmacokinetics

Absorption:
Ferrous gluconate is an oral iron supplement absorbed primarily in the proximal small intestine, notably the duodenum and upper jejunum. The ferrous (Fe2+) form of iron in gluconate salt facilitates its uptake via divalent metal transporter 1 (DMT1) expressed on enterocytes. Absorption efficiency is influenced by dietary factors, gastrointestinal pH, and the presence of competing minerals or medications. Typically, about 10-15% of the ingested dose is absorbed under normal iron status, but absorption increases markedly during iron deficiency states. Food can reduce absorption by forming insoluble complexes or by increasing gastric pH, hence ferrous gluconate is generally recommended to be taken on an empty stomach to maximize bioavailability. However, administration with food is permitted if gastrointestinal intolerance occurs.

Distribution:
Once absorbed, iron binds to transferrin in plasma for systemic distribution. Transferrin delivers iron primarily to the bone marrow for erythropoiesis, liver for storage as ferritin, and muscle tissue where it is incorporated into myoglobin. The effective plasma half-life of absorbed iron is brief as it is rapidly taken up by target tissues. Approximately 65-70% of body iron resides within hemoglobin of circulating erythrocytes. Tissue distribution is tightly regulated to prevent free iron-mediated oxidative damage via sequestration within ferritin and hemosiderin storage complexes.

Metabolism:
Ferrous gluconate itself is not metabolized enzymatically but undergoes oxidation from ferrous (Fe2+) to ferric (Fe3+) form after absorption as iron enters systemic circulation. Iron is then metabolized via incorporation into heme within erythroid precursors or stored intracellularly. The metabolic handling of iron is largely governed by regulatory proteins such as hepcidin, which controls intestinal absorption and macrophage iron recycling. Excess iron is stored safely to prevent toxicity.

Elimination:
Iron is eliminated from the body primarily via physiological loss of epithelial cells from skin, gastrointestinal tract, and minor amounts in urine and sweat; there is no active excretory mechanism. The daily loss amounts to approximately 1 mg in adults, necessitating dietary intake or supplementation to maintain balance. Excess iron can accumulate in tissues causing toxicity if intake exceeds requirements and homeostatic controls fail. Iron overload conditions such as hemochromatosis demonstrate impaired elimination. Management of iron dosing carefully considers these elimination dynamics to avoid adverse effects.

Dosage Forms

Available Dosage Forms:
Ferrous gluconate is commercially available primarily as oral tablets in the following strengths: 240 mg and 324 mg. These tablets contain ferrous gluconate delivering approximately 27 mg and 35 mg elemental iron respectively. The medication may also be found in liquid oral formulations for pediatric use, although the primary referenced forms are tablets.

Dosages for Adults and Adolescents:
For iron deficiency anemia, the initial adult dose is commonly 960 mg per day of ferrous gluconate (equivalent to 120 mg elemental iron) administered orally in divided doses 1 to 3 times daily for approximately 3 months. For vitamin and mineral supplementation, doses range from 48 to 144 mg daily of ferrous gluconate (6 to 18 mg elemental iron), adjusted by age and need. Adults over 51 may receive lower doses around 40 to 64 mg daily (5 to 8 mg elemental iron). Anemia associated with chronic renal failure may require higher doses up to 1600 mg daily (200 mg elemental iron) in divided doses.

Specific Patient Populations:
Pediatric dosing is weight- and age-dependent. For example, children ages 0 to 5 years are dosed at 24 to 48 mg/kg/day ferrous gluconate (3 to 6 mg/kg/day elemental iron). Older children and adolescents have dosages ranging from 480 mg to 960 mg daily. Preterm infants and infants under 1 year require carefully calculated lower doses based on body weight (e.g., 16 mg/kg/day in preterm infants). Pregnant and breastfeeding women should consult healthcare providers for individualized dosing adjustments reflecting increased iron demands.

Clinical Guidelines:
Ferrous gluconate should be administered on an empty stomach 1 hour before or 2 hours after meals to optimize absorption unless gastrointestinal upset occurs. Divided dosing improves tolerability and maintains stable serum iron levels. Patients with poor oral tolerance or inadequate response after 1 to 3 months may require intravenous iron therapy. Special attention is needed for patients with gastrointestinal diseases, hemoglobinopathies, or those receiving frequent transfusions to adjust dosage accordingly.

Mechanism Of Action

Ferrous gluconate acts as an oral iron supplement providing elemental iron essential for the synthesis of hemoglobin and myoglobin. The primary molecular mechanism involves the provision of ferrous ions (Fe2+), which are absorbed in the small intestine via specialized transporters including DMT1. This iron is then transported in the plasma bound to transferrin and delivered to erythroid marrow cells, where it is incorporated into protoporphyrin IX to form heme, the oxygen-binding component of hemoglobin.

At the cellular level, iron uptake supports erythropoiesis by enabling hemoglobin synthesis, thereby increasing the oxygen-carrying capacity of blood. Iron also contributes to the formation of myoglobin in muscle tissue, facilitating oxygen storage and utilization. On a biochemical level, iron is a vital cofactor for numerous enzymes involved in cellular respiration, DNA synthesis, and electron transport chains.

Clinically, the administration of ferrous gluconate replenishes depleted iron stores in iron deficiency anemia, correcting hypochromia and microcytosis characteristic of this condition. It also prevents the development of anemia in populations at risk. Compared to other oral iron salts like ferrous sulfate, ferrous gluconate may be better tolerated with fewer gastrointestinal side effects though delivering slightly less elemental iron per dose. Clinical studies have demonstrated efficacy in restoring hemoglobin levels and improving patient symptoms when adequate dosing and compliance are maintained.

Research into iron regulation has further elucidated the role of hepcidin in modulating iron absorption, suggesting that ferrous gluconate supplementation may be more effective when hepcidin levels are low, such as in iron deficiency or increased erythropoietic demand. Additionally, the pharmacokinetic profile of ferrous gluconate supports its use as a first-line oral iron therapy in both adults and pediatric populations with proven safety and efficacy profiles.

Pharmacological Actions

Provides supplemental iron critical for hemoglobin synthesis and erythropoiesis.
Replenishes iron stores depleted due to deficiency or increased physiological demands.
Increases oxygen delivery capacity by restoring normal hemoglobin and myoglobin levels.
Supports enzyme functions requiring iron as a cofactor in cellular metabolism and DNA synthesis.
Enhances muscle oxygen storage through myoglobin synthesis.
Facilitates correction of microcytic, hypochromic anemia symptoms.
Provides a bioavailable source of elemental iron absorbed through intestinal transporters.
Exhibits a relatively favorable tolerability profile compared to other oral iron salts.
Contributes to maintaining iron homeostasis when dietary intake is insufficient.
Reduces fatigue and weakness associated with iron deficiency anemia.
Helps prevent anemia during pregnancy and increased hematopoietic states.
May aid in supplementation for chronic kidney disease-associated anemia.

Therapeutic Or Clinical Uses

Treatment of iron deficiency anemia characterized by low hemoglobin and hematocrit levels.
Prevention of iron deficiency and associated anemia in populations at risk (e.g., pregnancy, menstruating women).
Supplementation in chronic kidney disease patients with anemia related to diminished erythropoiesis.
Adjunct therapy following blood loss due to surgery, trauma, or gastrointestinal bleeding.
Treatment of anemia secondary to nutritional deficiencies.
Supportive therapy in pediatric patients with iron deficiency or failure to thrive.
Part of prenatal vitamin regimens to prevent maternal and fetal iron deficiency.
Correction of anemia in patients with malabsorption syndromes or dietary insufficiency.
Management of anemia in hematological disorders such as thalassemia with iron deficiency.
Enhancement of oxygen delivery in athletes with documented iron deficiency.
Prevention of iron deficiency in infants, toddlers, and preterm neonates.
Supportive care in individuals with chronic illnesses leading to iron depletion.
Adjunct to erythropoiesis-stimulating agents in anemia treatment protocols.

Side Or Adverse Effects

Gastrointestinal discomfort including nausea and vomiting.
Constipation or diarrhea due to alterations in gut motility.
Abdominal pain or cramping.
Loss of appetite associated with oral iron intake.
Temporary green or dark coloration of stools as a benign side effect.
Extrinsic staining of teeth, especially with liquid formulations, reversible upon discontinuation.
Rare allergic reactions such as rash, itching, or hives.
Potential for serious adverse events including gastrointestinal bleeding manifested by bright red or black tarry stools.
Fever and signs of infection potentially related to iron overload.
Chest pain or throat discomfort upon tablet swallowing.
Risk of systemic toxicity or iron poisoning in cases of overdose, especially in children.
Metallic taste following oral administration.
Flatulence and bloating.
Hypersensitivity reactions including swelling of face, lips, or throat (anaphylaxis extremely rare).

Precautions

Avoid use in individuals with known hemochromatosis or hemosiderosis due to risk of iron overload.
Use cautiously in patients with a history of peptic ulcer disease or gastrointestinal inflammation.
Monitor for signs of iron overload in patients receiving chronic therapy or multiple transfusions.
Evaluate for thalassemia or other hemolytic anemias prior to initiation, as iron therapy can worsen these conditions.
Pregnant or lactating women should only use ferrous gluconate under medical supervision with dose adjustments.
Avoid concomitant use with antacids or mineral supplements that impair iron absorption unless advised by a physician.
Ensure accurate dosing in pediatric populations due to narrow therapeutic index and overdose risk.
Administer with caution in patients who have renal impairment and anemia, with appropriate dose titration.
Do not exceed recommended dosage to reduce risk of gastrointestinal toxicity and systemic complications.
Educate patients about the importance of adherence to dosing schedule and timing relative to meals.
Advise patients regarding potential for temporary teeth staining with liquid formulations and methods to minimize this effect.
Consider alternative routes of administration if oral therapy is not tolerated or ineffective.
Discontinue use if hypersensitivity or severe adverse reactions occur.
Use in combination with a balanced diet rich in iron to support treatment efficacy.

Warnings

Contraindicated in patients with hemochromatosis, a genetic iron overload disorder.
Do not use in individuals with hemosiderosis or other iron storage diseases.
Avoid in patients with hemolytic anemia due to potential exacerbation of iron burden.
Risk of fatal iron overdose in children; keep medication out of children’s reach.
Emergency medical attention required if signs of iron overdose occur, including vomiting, bloody diarrhea, and severe abdominal pain.
May cause serious gastrointestinal side effects such as bleeding, requiring prompt evaluation.
Use caution in patients with a history of ulcerative colitis or gastrointestinal ulceration.
Potential for allergic reactions, including swelling or difficulty breathing, warrants immediate discontinuation and emergency care.
Do not crush or chew extended-release formulations to prevent dose dumping and toxicity.
Iron supplementation may interfere with absorption of other concomitantly administered drugs.
Ensure proper storage away from heat and moisture to maintain drug strength.
Iron therapy should be part of comprehensive anemia management including diagnosis and treatment of underlying cause.
Continuous monitoring of hematologic parameters recommended during therapy.
Avoid administration with milk or dairy products due to decreased bioavailability.
Inform patients about the possibility of dark stools and differentiate from melena indicative of bleeding.

Contraindication

Known hypersensitivity or allergy to ferrous gluconate or any component of the formulation.
Hemochromatosis or idiopathic iron overload syndromes.
Hemosiderosis or other pathological iron storage conditions.
Hemolytic anemia, especially when due to red blood cell destruction and increased endogenous iron stores.
Patients with iron overload secondary to repeated blood transfusions unless explicitly monitored.
Any condition where iron therapy is not clinically indicated or may be harmful due to risk of toxicity.
Use in pediatric patients under 18 years without appropriate medical supervision.
Severe active gastritis or peptic ulceration until stabilized.
Known obstruction of the gastrointestinal tract.
Patients with known coagulation disorders who may be at increased risk of bleeding from gastrointestinal complications.
Avoid in the presence of other contraindicated medications that interact adversely with iron.
Do not administer in patients with unexplained anemia until etiology is established.
Incompatibility with parenteral therapies unless converted to approved intravenous iron forms.

Drug Interactions

Antacids (e.g., aluminum, magnesium-containing formulations) reduce absorption of ferrous gluconate when administered concomitantly.
Tetracycline antibiotics (e.g., doxycycline, minocycline) form complexes with iron reducing absorption and antibiotic efficacy.
Fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin, norfloxacin, ofloxacin) absorption impaired by iron administration.
Demeclocycline antibiotic efficacy reduced when co-administered with iron supplements.
Iron may decrease absorption of levodopa, penicillamine, and methyldopa.
Cholecystographic agents and bisphosphonates absorption may be interfered with by iron salts.
Concurrent use with vitamin C can enhance iron absorption but may increase gastrointestinal side effects.
Use caution with oral phosphate binders as iron may affect phosphate balance.
Iron may reduce the bioavailability of thyroid hormone preparations if taken simultaneously.
Potential interaction with certain antivirals and antiretrovirals affecting iron status and drug absorption.
Chelating agents such as deferoxamine may reduce iron levels and interfere with therapy.
Avoid simultaneous administration with calcium supplements which can inhibit iron absorption.
Iron may interfere with diagnostic tests such as fecal occult blood testing.
Monitor for drug interactions in polypharmacy patients, especially older adults.
Separate dosing by at least 2 hours before or after interacting medications to maximize efficacy.

Preparations Of The Drug

Oral tablets of ferrous gluconate available in strengths of 240 mg and 324 mg.
Liquid oral formulations for pediatric and patients with swallowing difficulties (specific concentrations vary).
Extended-release formulations designed to reduce gastrointestinal side effects and improve adherence.
Combination products with multivitamins or minerals for comprehensive supplementation.
Prescribed dosing devices such as dosing syringes for accurate administration of liquid preparations.
Standard tablet formulations intended for oral administration with water or juice.
Formulations for adults and pediatric patients with varying elemental iron content.
Products packaged for outpatient use with patient informational leaflets on dosing and side effects.
Bulk powder forms used in compounding pharmacies for customized dosing preparations.
Coated and uncoated tablets to address palatability and gastrointestinal tolerance.
Generic and brand-name products marketed under names such as Fergon, Ferate, Ferralet, and Simron.
Preparation storage guidance includes room temperature in dry conditions, protected from heat and moisture.
Non-oral forms such as intravenous or parenteral iron exist but are separate pharmaceutical entities from ferrous gluconate.
Standardized dosing measurement tools recommended to ensure precise patient administration.
Instructions for use emphasize not crushing or chewing extended-release preparations to maintain proper release.